See more : Muhak Co., Ltd. (033920.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Schrödinger, Inc. (SDGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Schrödinger, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Magnora ASA (MGN.OL) Income Statement Analysis – Financial Results
- Electromedical Technologies, Inc. (EMED) Income Statement Analysis – Financial Results
- Excite Holdings Co., Ltd. (5571.T) Income Statement Analysis – Financial Results
- Huaneng Power International, Inc. (HNP) Income Statement Analysis – Financial Results
- Prism Johnson Limited (PRSMJOHNSN.BO) Income Statement Analysis – Financial Results
Schrödinger, Inc. (SDGR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.schrodinger.com
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 216.67M | 180.96M | 137.93M | 108.10M | 85.54M | 66.64M | 55.69M |
| Cost of Revenue | 75.97M | 79.93M | 72.31M | 44.62M | 36.45M | 23.70M | 15.89M |
| Gross Profit | 140.69M | 101.02M | 65.62M | 63.47M | 49.09M | 42.94M | 39.80M |
| Gross Profit Ratio | 64.93% | 55.83% | 47.57% | 58.72% | 57.39% | 64.43% | 71.46% |
| Research & Development | 181.77M | 126.37M | 90.90M | 64.70M | 39.40M | 34.52M | 27.67M |
| General & Administrative | 99.15M | 90.83M | 64.01M | 41.90M | 27.04M | 18.55M | 14.44M |
| Selling & Marketing | 37.23M | 30.64M | 22.15M | 17.80M | 21.36M | 17.83M | 16.72M |
| SG&A | 136.37M | 121.47M | 86.16M | 59.69M | 48.40M | 36.38M | 31.15M |
| Other Expenses | 0.00 | 3.95M | 1.06M | 2.25M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 318.14M | 247.84M | 177.06M | 124.39M | 87.81M | 70.91M | 58.82M |
| Cost & Expenses | 394.11M | 327.77M | 249.37M | 169.01M | 124.26M | 94.61M | 74.71M |
| Interest Income | 0.00 | 3.95M | 1.06M | 2.25M | 1.88M | 433.00K | 359.00K |
| Interest Expense | 0.00 | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M | 1.69M |
| EBITDA | -171.90M | -142.47M | -108.60M | -57.26M | -35.08M | -25.08M | -17.34M |
| EBITDA Ratio | -79.34% | -80.01% | -86.97% | -79.12% | -52.60% | -36.41% | -28.18% |
| Operating Income | -177.45M | -149.12M | -111.44M | -60.92M | -38.72M | -27.97M | -19.02M |
| Operating Income Ratio | -81.90% | -82.41% | -80.80% | -56.35% | -45.26% | -41.97% | -34.15% |
| Total Other Income/Expenses | 220.37M | -2.31M | 10.64M | 34.62M | 12.74M | -379.00K | 1.96M |
| Income Before Tax | 42.92M | -149.13M | -100.81M | -26.29M | -25.97M | -28.35M | -17.06M |
| Income Before Tax Ratio | 19.81% | -82.41% | -73.09% | -24.32% | -30.36% | -42.54% | -30.63% |
| Income Tax Expense | 2.20M | 63.00K | 411.00K | 345.00K | -291.00K | 77.00K | 332.00K |
| Net Income | 40.72M | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M | -17.39M |
| Net Income Ratio | 18.79% | -82.45% | -73.38% | -24.64% | -30.02% | -42.66% | -31.23% |
| EPS | 0.57 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| EPS Diluted | 0.54 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| Weighted Avg Shares Out | 71.78M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
| Weighted Avg Shares Out (Dil) | 74.99M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
2 Bill Gates stocks to turn $100 into $1,000 by 2025
The 3 Best Med Tech Stocks to Buy Now
Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
3 Small-Cap Stocks to Buy at a 52-Week Low
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3 Top-Rated Gene Editing Stocks Actually Making Money
Source: https://incomestatements.info
Category: Stock Reports